GILD

#88
Gilead Sciences, Inc. - Common Stock
135.5 2 USD
-0.04%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
134.58
136.48
Year Range
104.46
157.27
Daily Change
-0.04%
Monthly Change
+5.91%
6 month change
+7.82%
Year Change
+21.41%
Previous Close
135.5 8
Open
135.4 1
Low
134.5 8
High
136.4 8
Volume
1 759
Open full chart Full chart

Financials

Overview Statement Statistics Dividends
Quarterly Annual
  • Market Capitalization 168.26 B
  • Employee 17 K
  • Founded 1987
  • CEO Daniel O'Day
  • Website www.gilead.com
  • Headquarter Delaware, United States
  • FIGI BBG000CKGBP2
  • Industry Drug Manufacturers—General
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
18.96
Price to sales ratio
5.88
Dividends per share
0.82
Dividend yield %
3.99

Gilead Sciences, Inc. - Common Stock

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. It has recently expanded into different therapeutic areas such as oncology and inflammation. Gilead is a member of the Nasdaq-100 and the S&P 100. Gilead was founded in 1987 under the name Oligogen by Michael L. Riordan. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs like Tamiflu and Vistide that decade. In the 2000s, Gilead received approval for drugs including Viread and Hepsera, among others. It began evolving from a biotechnology company into a pharmaceutical company, acquiring several subsidiaries, though it still relied heavily on contracting to manufacture its drugs. The company continued its growth in the 2010s.

News